Simplified within-host and dose-response models of SARS-CoV-2

DOI10.1016/J.JTBI.2023.111447MaRDI QIDQ6174192zbMATH OpenFDO

Authors Jingsi Xu, Jonathan Carruthers, Thomas Finnie, Ian M. Hall

Publication date 14 July 2023

Published in Journal of Theoretical Biology (Search for Journal in Brave)

zbMATH Keywords

dose-responseSARS-CoV-2within-host models

Mathematics Subject Classification ID

Epidemiology (92D30)

Recommendations

• Multiple cohort study of hospitalized SARS-CoV-2 in-host infection dynamics: parameter estimates, identifiability, sensitivity and the eclipse phase profile
• Parsimonious models of in-host viral dynamics and immune response
• A mathematical model of within-host COVID-19 dynamics
• Dynamics of SARS-CoV-2 infection model with two modes of transmission and immune response
• The within-host viral kinetics of SARS-CoV-2

Cites work

• scientific article; zbMATH DE number 3863589 (Why is no real title available?)
• Modeling amantadine treatment of influenza A virus in vitro
• Modeling the viral dynamics of SARS-CoV-2 infection

Cited in

(10)

• A mathematical model of within-host COVID-19 dynamics
• Why, when and how should exposure be considered at the within-host scale? A modelling contribution to PRRSv infection
• A simple in-host model for COVID-19 with treatments: model prediction and calibration
• Multiple cohort study of hospitalized SARS-CoV-2 in-host infection dynamics: parameter estimates, identifiability, sensitivity and the eclipse phase profile
• Modeling identifies variability in SARS-CoV-2 uptake and eclipse phase by infected cells as principal drivers of extreme variability in nasal viral load in the 48 h post infection
• The within-host viral kinetics of SARS-CoV-2
• Modelling how increased Cathepsin B/L and decreased TMPRSS2 usage for cell entry by the SARS-CoV-2 Omicron variant may affect the efficacy and synergy of TMPRSS2 and Cathepsin B/L inhibitors
• A mechanistic modeling and estimation framework for environmental pathogen surveillance
• Relationship between the inclusion/exclusion criteria and sample size in randomized controlled trials for SARS-CoV-2 entry inhibitors
• A model for SARS-CoV-2 infection with treatment

This page was built for publication: Simplified within-host and dose-response models of SARS-CoV-2

Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q6174192)